Elixirgen Therapeutics Appoints Jeffrey L. Cleland, Ph.D., to Board of Directors - read this article along with other careers information, tips and advice on BioSpace
Elixirgen Therapeutics Presents New Clinical Data Demonstrating Ex Vivo Telomere Elongation with EXG-34217 in Dyskeratosis Congenita at the 64th ASH Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
BALTIMORE, May 25, 2021 /PRNewswire/ Elixirgen Therapeutics, Inc., a Baltimore-based biotechnology company focused on the discovery and development of therapies for genetic diseases and vaccines, today announced the dosing of the first and second participants in its COVID-19 vaccine Phase 1/2 Clinical Trial in Japan.
The vaccine, called EXG-5003, is an intradermally-injected, temperature-controllable, self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein.
Elixirgen Therapeutics Announces First Dosing of COVID19 Vaccine EXG-5003 in Phase 1/2 Trial at Fujita Health University
Akihiro Ko, CEO of Elixirgen Therapeutics, said We are pleased to begin our Phase 1/2 study for EXG-5003, which has been in development since March of 2020. There is an ongoing global need for COVID-19 vaccines, and we believe in the importance of contributing to the public health effort.
Baltimore's Elixirgen Therapeutics raises $4M to fuel trials for Covid vaccine, rare disease drug bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.